Literature DB >> 12570659

Oncogenic signaling pathways activated by RON receptor tyrosine kinase.

Alla Danilkovitch-Miagkova1.   

Abstract

RON (Receptuer d'Origine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i). RON is overexpressed and constitutively active in some primary tumors and tumor cell lines; (ii). experimental mutations of RON cause oncogenic cell transformation, and (iii). RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase/AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570659     DOI: 10.2174/1568009033333745

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  22 in total

1.  The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Authors:  Peter T Yu; Michele Babicky; Dawn Jaquish; Randy French; Karly Marayuma; Evangeline Mose; Sherry Niessen; Heather Hoover; David Shields; David Cheresh; Benjamin F Cravatt; Andrew M Lowy
Journal:  Int J Cancer       Date:  2012-03-08       Impact factor: 7.396

2.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

3.  Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Authors:  Devikala Gurusamy; Sasha J Ruiz-Torres; Abby L Johnson; Dana A Smith; Susan E Waltz
Journal:  Mech Dev       Date:  2014-07-15       Impact factor: 1.882

4.  Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.

Authors:  Cho-Yun Chung; Young-Lan Park; Young-A Song; Eun Myung; Kyu-Yeol Kim; Gi-Hoon Lee; Ho-Seok Ki; Kang-Jin Park; Sung-Bum Cho; Wan-Sik Lee; Young-Do Jung; Kyung-Keun Kim; Young-Eun Joo
Journal:  Dig Dis Sci       Date:  2011-09-08       Impact factor: 3.199

5.  RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.

Authors:  Jun-Feng Chen; Bi-Xia Yu; Liang Ma; Xiu-Yi Lv; Jun-Hui Jiang; Qi Ma
Journal:  Oncol Lett       Date:  2018-02-28       Impact factor: 2.967

6.  The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis.

Authors:  Sara E Meyer; Glendon M Zinser; William D Stuart; Peterson Pathrose; Susan E Waltz
Journal:  Dev Biol       Date:  2009-07-01       Impact factor: 3.582

Review 7.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice.

Authors:  Sara E Meyer; Susan E Waltz; Kathleen H Goss
Journal:  Mol Carcinog       Date:  2009-11       Impact factor: 4.784

Review 9.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

10.  The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Authors:  Xiangmin Tong; Xuewu Zhang; Jian Fan; Yin Tong; Shuangshuang Li; Jie Jin; Hangping Yao
Journal:  Cancer Biol Ther       Date:  2013-01-29       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.